Lundbeckfonden Emerge

investment firm

About

Lundbeckfonden Emerge is a strategic initiative of the Lundbeckfonden established in the spring of 2012.

Details

Industries
Finance
Founded date
Jan 1, 2012
Operating Status
Active
Investor Type
Accelerate

Lundbeckfonden Emerge seeks to identify and initiate commercial development of scientific opportunities which it considers from its analysis have high commercial potential. The main objective is to turn scientific discoveries and early stage opportunities into commercial ventures with a maturity that allows for full venture financing.

Lundbeckfonden Emerge not only offers limited financing for selected cases but also offers seasoned advice or direct participation in new ventures, as part of its unique model to optimize the outcome of the venture to the benefit of all stakeholders. Lundbeckfonden Emerge will seek to develop select projects together with founders and will take on an active role from mentoring to active project management, as is considered optimal for the outcome of the specific project. In this way, Lundbeckfonden Emerge is not a replication of traditional seed funds, but rather a unique way of using research funds to get to commercially viable projects.

Investments

Number of Investments
Number of Lead Investments
7
2
Lundbeckfonden Emerge has made 7 investments. Their most recent investment was on Feb 15, 2022, when NMD Pharma raised €35M.
Date Company Name
Round Money Raised Industry Lead Investor
Feb 15, 2022 NMD Pharma
Series Unknown €35M Biotechnology
May 4, 2021 Cytoki Pharma
Series A $45M Biotechnology Yes
Jan 13, 2021 IO Biotech
Series B €127M Biotechnology
Jun 24, 2019 AFYX Therapeutics
Debt Financing $13M Biotechnology
Mar 23, 2018 NMD Pharma
Series A €38M Biotechnology

Employee Profiles

Number of Employee Profiles
1
Lundbeckfonden Emerge has 1 current employee profiles, including Executive Christian E. Elling

Exits

Lundbeckfonden Emerge has had 1 exits. Lundbeckfonden Emerge most notable exits include IO Biotech

Date Company Name Exit Type Industry
Nov 5, 2021 IO Biotech IPO Biotechnology Detail